These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37338025)

  • 1. SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307.
    Feng D; He J; Yuan M; Chen Q; Zeng X; Zhou Q; Wu J; Han B
    Biofactors; 2023; 49(6):1158-1173. PubMed ID: 37338025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
    Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
    Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUMOylation of HSP27 by small ubiquitin-like modifier 2/3 promotes proliferation and invasion of hepatocellular carcinoma cells.
    Ge H; Du J; Xu J; Meng X; Tian J; Yang J; Liang H
    Cancer Biol Ther; 2017 Aug; 18(8):552-559. PubMed ID: 28665748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration, invasion and chemoresistance.
    Jiang Z; Hou Z; Liu W; Yu Z; Liang Z; Chen S
    Bioengineered; 2022 Jan; 13(1):810-823. PubMed ID: 34974791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
    Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
    Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
    Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
    Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small ubiquitin-related modifier 2/3 interacts with p65 and stabilizes it in the cytoplasm in HBV-associated hepatocellular carcinoma.
    Liu J; Sha M; Wang Q; Ma Y; Geng X; Gao Y; Feng L; Shen Y; Shen Y
    BMC Cancer; 2015 Oct; 15():675. PubMed ID: 26458400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
    Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
    Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
    J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
    Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ; Lin HY; Zhang Y; Chen WF
    J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
    Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
    Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer.
    Liu YL; Xiang Z; Zhang BY; Zou YW; Chen GL; Yin L; Shi YL; Xu LL; Bi J; Wang Q
    Aging (Albany NY); 2024 Jun; 16(11):9410-9436. PubMed ID: 38848145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SUMOylation of Nuclear γ-Actin by SUMO2 supports DNA Damage Repair against Myocardial Ischemia-Reperfusion Injury.
    Zhao W; Zhang X; Zhao J; Fan N; Rong J
    Int J Biol Sci; 2022; 18(11):4595-4609. PubMed ID: 35864967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance.
    Li J; Lv J; Chen Y; Li L
    Gene; 2023 May; 864():147323. PubMed ID: 36858188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity.
    Di Y; Jing X; Hu K; Wen X; Ye L; Zhang X; Qin J; Ye J; Lin R; Wang Z; He W
    Drug Resist Updat; 2023 Jan; 66():100909. PubMed ID: 36525936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
    Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
    Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.